Patents by Inventor Hans Ageland
Hans Ageland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230131227Abstract: The present invention provides a pharmaceutical composition comprising a reversely thermo-reversible hydrogel as active ingredient, for administration to the eye of mammalian subjects. In particular, it relates to a pharmaceutical composition for use in, and a method for, the ophthalmic treatment of dry eye disease.Type: ApplicationFiled: March 12, 2021Publication date: April 27, 2023Inventors: Martin VIDAEUS, Hans AGELAND, Ulf BJÖRKLUND, Gerhard GARHÖFER
-
Patent number: 8574569Abstract: A composition is provided, which comprises a serine protease; a reversible inhibitor of said serine protease; and a stabilizing agent M having the formula I: Also provided are uses of the composition as a medicament, and other uses and methods employing its various properties.Type: GrantFiled: February 6, 2013Date of Patent: November 5, 2013Assignee: Trobio ABInventors: Lars-Olov Andersson, Hans Ageland
-
Patent number: 8394372Abstract: A composition is provided, which comprises a serine protease; a reversible inhibitor of said serine protease; and a stabilizing agent M having the formula I: Also provided are uses of the composition as a medicament, and other uses and methods employing its various properties.Type: GrantFiled: September 21, 2005Date of Patent: March 12, 2013Assignee: Trobio ABInventors: Lars-Olov Andersson, Hans Ageland
-
Publication number: 20090136474Abstract: A composition is provided, which comprises a serine protease; a reversible inhibitor of said serine protease; and a stabilizing agent M having the formula I: Also provided are uses of the composition as a medicament, and other uses and methods employing its various properties.Type: ApplicationFiled: September 21, 2005Publication date: May 28, 2009Inventors: Lars-Olov Andersson, Hans Ageland
-
Patent number: 7193056Abstract: The present invention relates to a process for purifying a hydrophobic or amphiphilic compound, by first mixing a starting material containing the hydrophobic or amphiphilic compound with a first polymeric material, water and at least one of a second polymeric material and a surfactant, wherein the first polymeric material and the second polymeric material and/or surfactant are immiscible in the resulting primary aqueous solution. The process further comprises maintaining the primary aqueous solution for a period of time sufficient for essentially separating the phases formed, and then removing the phase containing the main portion of the hydrophobic or amphiphilic compound and the second polymeric material and/or surfactant. The second polymeric material and/or surfactant are separated from the hydrophobic or amphiphilic compound, and subsequently recycled to the initial mixing step.Type: GrantFiled: June 8, 2004Date of Patent: March 20, 2007Assignee: Pharmacia & UpJohn ABInventors: Hans Ageland, Lena Nyström, Josefine Persson, Folke Tjerneld
-
Publication number: 20040225120Abstract: The present invention relates to a process for purifying a hydrophobic or amphiphilic compound, by first mixing a starting material containing the hydrophobic or amphiphilic compound with a first polymeric material, water and at least one of a second polymeric material and a surfactant, wherein the first polymeric material and the second polymeric material and/or surfactant are immiscible in the resulting primary aqueous solution. The process further comprises maintaining the primary aqueous solution for a period of time sufficient for essentially separating the phases formed, and then removing the phase containing the main portion of the hydrophobic or amphiphilic compound and the second polymeric material and/or surfactant. The second polymeric material and/or surfactant are separated from the hydrophobic or amphiphilic compound, and subsequently recycled to the initial mixing step.Type: ApplicationFiled: June 8, 2004Publication date: November 11, 2004Inventors: Hans Ageland, Lena Nystrom, Josefine Persson, Folke Tjernelo
-
Patent number: 6767994Abstract: The present invention relates to a process for purifying a hydrophobic or amphiphilic compound, by first mixing a starting material containing the hydrophobic or amphiphilic compound with a first polymeric material, water and at least one of a second polymeric material and a surfactant, wherein the first polymeric material and the second polymeric material and/or surfactant are immiscible in the resulting primary aqueous solution. The process further comprises maintaining the primary aqueous solution for a period of time sufficient for essentially separating the phases formed, and then removing the phase containing the main portion of the hydrophobic or amphiphilic compound and the second polymeric material and/or surfactant. The second polymeric material and/or surfactant are separated from the hydrophobic or amphiphilic compound, and subsequently recycled to the initial mixing step.Type: GrantFiled: May 16, 2000Date of Patent: July 27, 2004Assignee: Pharmacia ABInventors: Hans Ageland, Lena Nyström, Josefine Persson, Folke Tjerneld
-
Patent number: 6559284Abstract: The present invention relates to a composition for use in purification of apolipoprotein A (ApoA) or apolipoprotein E (ApoE), said composition comprising a first and a second polymeric material, wherein the first and second polymeric material are immiscible in the primary aqueous solution, and wherein the second polymeric material is amphiphilic and water soluble. The invention further relates to a process for purifying ApoA or ApoE, or variants or mixtures thereof, by first mixing ApoA or ApoE, the composition containing a first and second polymeric material and water. The resulting primary aqueous solution is maintained for a period of time sufficient for essentially separating the phases formed, and removing the phase containing the second polymeric material and the main portion of ApoA or ApoE. Subsequently, the second polymeric material is separated from ApoA or ApoE.Type: GrantFiled: September 5, 1997Date of Patent: May 6, 2003Assignee: Esperion Therapeutics, Inc.Inventors: Hans Ageland, Lena Nyström, Josefine Persson, Folke Tjerneld
-
Patent number: 6506879Abstract: A substantially endotoxin-free ApoA or ApoE is produced by recombinant DNA technique, suitably in E. coli. Medicaments and methods for treatment of atherosclerosis or cardiovascular diseases employ ApoA or ApoE purified by a process comprising contacting a first aqueous solution comprising ApoA or ApoE and endotoxins with a matrix comprising an immobilized compound with an end group comprising two or three nitrogen atoms bonded to a carbon atom for attaching the endotoxins to the matrix, and subsequently treating the matrix comprising the immobilized compound with a second aqueous solution comprising a surfactant for releasing the ApoA or ApoE while the endotoxins remain attached to the matrix.Type: GrantFiled: November 22, 1999Date of Patent: January 14, 2003Assignee: Esperion Therapeutics, Inc.Inventors: Hans Ageland, Lena Romander
-
Patent number: 6107467Abstract: The present invention relates to a process for purifying a hydrophobic or amphiphilic compound, by first mixing a starting material containing the hydrophobic or amphiphilic compound with a first polymeric material, water and at least one of a second polymeric material and a surfactant, wherein the first polymeric material and the second polymeric material and/or surfactant are immiscible in the resulting primary aqueous solution. The process further comprises maintaining the primary aqueous solution for a period of time sufficient for essentially separating the phases formed, and then removing the phase containing the main portion of the hydrophobic or amphiphilic compound and the second polymeric material and/or surfactant. The second polymeric material and/or surfactant are separated from the hydrophobic or amphiphilic compound, and subsequently recycled to the initial mixing step.Type: GrantFiled: September 5, 1997Date of Patent: August 22, 2000Assignee: Pharmacia & Upjohn ABInventors: Hans Ageland, Lena Nystrom, Josefine Persson, Folke Tjerneld
-
Patent number: 5990081Abstract: A substantially endotoxin-free ApoA or ApoE is produced by recombinant DNA technique, suitably in E. coli. Medicaments and methods for treatment of atherosclerosis or cardiovascular diseases employ ApoA or ApoE purified by a process comprising contacting a first aqueous solution comprising ApoA or ApoE and endotoxins with a matrix comprising an immobilized compound with an end group comprising two or three nitrogen atoms bonded to a carbon atom for attaching the endotoxins to the matrix, and subsequently treating the matrix comprising the immobilized compound with a second aqueous solution comprising a surfactant for releasing the ApoA or ApoE while the endotoxins remain attached to the matrix.Type: GrantFiled: August 5, 1998Date of Patent: November 23, 1999Assignee: Esperion Therapeutics, Inc.Inventors: Hans Ageland, Lena Romander
-
Patent number: 5834596Abstract: A process for purifying apolipoprotein A (ApoA) or apolipoprotein E (ApoE), or variants or mixtures thereof, comprises contacting a first aqueous solution comprising ApoA or ApoE and endotoxins with a matrix comprising an immobilized compound with an end group comprising two or three nitrogen atoms bonded to a carbon atom for attaching the endotoxins to the matrix, and subsequently treating the matrix comprising the immobilized compound with a second aqueous solution comprising a surfactant for releasing the ApoA or ApoE while the endotoxins remain attached to the matrix.Type: GrantFiled: July 17, 1997Date of Patent: November 10, 1998Assignee: Pharmacia & Upjohn ABInventors: Hans Ageland, Lena Romander